Skip to main content

Table 1 Immunisation study groups, treatments and outcomes

From: Duration of protective immunity and antibody responses in cattle immunised against alcelaphine herpesvirus-1-induced malignant catarrhal fever

Animal No. Group Vaccine/ Controla Challenge dayb Day euthanizedc Virus DNA in blood at PM Pathologydsummary Days to clinical MCF
805 1 Vaccine 63 100 pos MCF 37
789 1 Vaccine 63 103 pos MCF 40
792 1 Vaccine 63 119 pos MCF 56
568 1 Vaccine 63 139 neg -  
570 1 Vaccine 63 139 neg -  
785 1 Vaccine 63 140 neg -  
822 1 Vaccine 63 140 neg -  
807 1 Vaccine 63 140 neg -  
575 1 Control 63 84 pos MCF 21
787 1 Control 63 93 pos MCF 30
814 1 Control 63 96 pos MCF 33
808 1 Control 63 103 pos MCF 40
785 1 Control 63 103 pos MCF 40
149 1 Control 63 107 pos MCF 44
821 1 Control 63 116 pos MCF 53
781 1 Control 63 128 pos MCF 65
861 2 Vaccine 77 152 neg -  
702 2 Vaccine 77 152 neg -  
214 2 Vaccine 77 153 neg -  
774 2 Vaccine 77 153 neg -  
769 2 Vaccine 77 153 neg -  
090 2 Vaccine 77 154 neg -  
967 2 Vaccine 77 154 neg -  
968 2 Vaccine 77 154 neg -  
165 2 Control 77 110 pos MCF 33
700 2 Control 77 152 neg -  
856 3 Vaccine 182 212 pos MCF 30
776 3 Vaccine 182 217 pos MCF 35
965 3 Vaccine 182 224 pos MCF 42
701 3 Vaccine 182 257 pos MCF 75
862 3 Vaccine 182 257 neg non-specific  
611 3 Vaccine 182 257 neg non-specific  
770 3 Vaccine 182 258 neg -  
699 3 Vaccine 182 258 neg -  
326 3 Control 182 217 pos MCF 35
023 3 Control 182 250 pos MCF 68
019 4 Vaccine 273 305 pos MCF 32
969 4 Vaccine 273 310 pos MCF 37
613 4 Vaccine 273 315 pos MCF 42
771 4 Vaccine 273 320 pos MCF 47
195 4 Vaccine 273 348 pos MCF 75
966 4 Vaccine 273 348 neg non-specific  
768 4 Vaccine 273 349 neg -  
772 4 Vaccine 273 349 neg -  
719 4 Control 273 300 pos MCF 27
620 4 Control 273 302 pos MCF 29
  1. a Vaccinated animals in all groups received the same dose (10 mL of 107 TCID50 per mL) of vaccine for both prime and boost, given intramuscularly with 20% (v/v) Emulsigen. Control animals in each group received virus-free culture medium with Emulsigen, prepared and administered in the same way.
  2. b Pathogenic AlHV-1 challenge for each group was as follows: group 1 received 10 mL of 104.7 TCID50/mL virus; group 2 received 10 mL of 103.8 TCID50/mL virus; and groups 3 and 4 received 10 mL of 104.05 TCID50/mL virus, administered intranasally in all groups.
  3. c All animals were monitored daily for clinical signs of MCF, including fever, loss of appetite, depression, nasal or ocular discharge and conjunctivitis. A clinical scoring scheme (Additional file 1 Table S 1) was used to ensure that all animals were euthanized at the onset of moderate clinical signs. Animal that did not develop clinical signs of MCF were euthanized for post-mortem at least 75 days after challenge. d Pathology was assessed as described in the text and is summarised as MCF, non-specific or negative (−). Tissue sections from animals with non-specific pathology were tested for presence of AlHV-1 DNA by real-time PCR. No viral DNA was detected in any sample with non-specific pathology.